Compare Ascendis Pharma A/S (ASND) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Yum China Holdings Inc — how do they compare? Ascendis Pharma A/S trades at $270.25 (market cap $17.74B), while Yum China Holdings Inc trades at $43.96 (market cap $14.80B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Yum China Holdings Inc pays a 2.7% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | YUMC | |
|---|---|---|
Market Cap | $17.74B | $14.80B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $57.95 |
52-Week Low | $163.32 | $40.18 |
Enterprise Value | $18.11B | $15.69B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
YUMC trades at $43.02, up 1.68% today, with a neutral technical signal and strong fundamentals including consistent earnings beats. Revenue grew to $11.80B in 2025, with a net margin of 7.83%. The company recently announced a $0.29 dividend and a $512M share repurchase, while acquiring full ownership of Pizza Hut in mainland China, signaling strategic expansion.
Outlook remains positive with analyst consensus at 74% buy ratings, though risks include China's competitive dining market and currency volatility. The stock's P/E of 16.48 and ROE of 16.87% support value, but investors should monitor Q2 2026 earnings due July 30, 2026, for growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
